EAM
LKFT

EverPoint Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

EverPoint Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-49,981
Closed -$3.14M – 455
2015
Q4 		$3.14M Buy
+49,981
New +$2.55M 0.07% 333

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EverPoint Asset Management's LKFT Position: Q1 2016 in Review

EverPoint Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2016, closing a stake of 49,981 shares — an estimated $3.14M sold.

EverPoint Asset Management first reported a position in LKFT in Q4 2015 and held it in 1 quarter. The position peaked at $3.14M in Q4 2015. 32 funds tracked by Wall St. Rank hold LKFT as of Q1 2016.

  • EverPoint Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2016 after selling out during the quarter.
  • EverPoint Asset Management sold 49,981 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2016, an estimated $3.14M.
  • EverPoint Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2015 and held it in 1 quarter.
  • EverPoint Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $3.14M in Q4 2015.
  • 32 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2016.

Based on EverPoint Asset Management's 13F filing for Q1 2016, filed 16 May 2016.